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ABSTRACT 
Background: Chronic kidney failure (CKF) patients experience impaired functional 
cardiovascular reserve with reduced oxygen consumption at peak exercise (VO2peak). 
No studies have examined whether this is related to impaired cardiovascular 
compliance as a consequence of loss of adaptive structural alterations, resulting from 
chronic uremia or hypertension.  
Study Design: Prospective matched cohort study. 
Setting & Participants: We assessed CKF in parallel with patients with essential 
hypertension but without cardiovascular disease (CVD). The CKF subjects were either 
scheduled for kidney transplantation or transplant-waitlisted. 80 CKF and 80 essential 
hypertension subjects matched in age, sex and BMI were evaluated. 61 CKF patients 
(76.3%) were dialysis-dependent. 
Predictor: CKF versus essential hypertension without CVD. 
Measurements and outcomes: VO2peak was measured during maximal exercise 
testing. 2D-echocardiography and arterial applanation tonometry were performed prior 
to exercise testing. To evaluate for the difference in VO2peak between the study 
groups, statistically significant predictors of VO2peak in multiple regression models 
were additionally assessed by fitting models comprising the interaction term of patient 
group with the predictor variable of interest. 
Results: VO2peak was significantly lower in CKF than essential hypertension subjects 
(18.8 vs. 24.5 ml/min/kg, p<0.001). Independent predictors of VO2peak for CKF 
included LV filling pressure (E/mean e') (unstandardized regression coefficient, b=-5.1) 
and pulse wave velocity (PWV) (b=-4.0); in essential hypertension, these were LV 
mass index (b=0.2), LV end-diastolic volume index (LVEDVI) (b=0.4), peak heart rate 
(HR) (b=0.2) and PWV (b=-8.8). The interaction effect of VO2peak between patient 
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groups with LV mass index (∆B=-0.2, p<0.001), LVEDVI (∆B=-0.4, p<0.001) and peak 
HR (∆B=-0.1, p<0.01) were significantly stronger in the hypertension group whereby 
higher values led to greater VO2peak.  
Limitations: Skeletal muscle strength was not assessed. 
Conclusion: This study suggests that maladaptive LV changes as well as blunted 
chronotropic response are important mechanistic factors resulting in reduced 
cardiovascular reserve in CKF patients, beyond predominantly vascular changes 
associated with hypertension. 
 
 
 
 
 
 
 
 
 
 
 
 
  4 
INTRODUCTION 
Patients with chronic kidney failure (CKF) are at high risk of cardiovascular 
disease (CVD)1.  Complex changes in both the cardiac and vascular systems result in 
structural and functional changes that can lead to reduced exercise tolerance, quality 
of life, increased morbidity and ultimately premature death2.  CKF causes arterial 
stiffening resulting in reducing arterial cushioning of phasic pressure changes3. The 
resulting increase in left ventricular (LV) afterload combined with a host of metabolic 
stimuli including inflammation, oxidative stress, renin-angiotensin system activation, 
changes in phosphate metabolism and production of FGF-23 promotes an increase in 
LV mass and reduced myocardial perfusion4 5-7. The hemodynamic sequelae of such 
morphological alterations imply a high cardiac energy expenditure and elevated 
oxygen consumption in the myocardium.  
The LV abnormalities in CKF reflect both myocyte hypertrophy and ultra-
structural changes such as myocardial fibrosis8. These changes result in impaired 
myocardial relaxation and elevation of LV filling pressure8,9. This impairment in 
diastolic function along with more subtle changes in systolic function leads to a high 
incidence of heart failure (HF)3,6,10 with a reduction in exercise capacity11.  Oxygen 
consumption at peak exercise (VO2peak) is a metric that provides an index of exercise 
capacity and represents the cardiovascular system’s ability to take up, distribute and 
utilize oxygen at maximal exercise.  Reduced values of VO2peak have been shown to 
predict prognosis in the HF population12,13.  Several studies have also demonstrated a 
reduced VO2peak in patients with CKF
14-16 and this was also associated with poor 
survival14,17. The precise relationship between adverse structural alterations of the 
cardiovascular system and VO2peak in CKF patients is currently unknown.  
In this study, we hypothesized that increased LV mass, filling pressure and 
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arterial stiffness are associated with reduced VO2peak in patients with CKF. Using a 
control group of patients with treated essential hypertension but without CVD we also 
investigated the hypothesis that the main determinants of structural and functional 
cardiovascular changes and VO2peak in CKF are a result of mechanisms other than 
hypertension.  
 
METHODS 
Study Design and Clinical Data 
Inclusion criteria were patients aged ≥18 who were either waitlisted or 
scheduled for kidney transplantation at our center, University Hospitals Coventry and 
Warwickshire NHS Trust, United Kingdom. In parallel, individuals with treated 
essential hypertension but without evidence of CVD (HF, ischemic heart disease, 
cerebrovascular disease), diabetes or secondary causes of hypertension were 
recruited at random from the community through primary care database. In both 
groups, patients with pre-existing chronic lung disease were excluded.  All recruited 
patients underwent cardiopulmonary exercise testing (CPET), arterial applanation 
tonometry and a study-specified echocardiogram. For patients who were hemodialysis 
dependent, these assessments were carried out on the first non-dialysis day that was 
at least 12 hours after the last dialysis session in order to avoid the effects of 
hemodialysis-induced myocardial stunning18 and minimize the impact of volume load 
variability on the indices of cardiovascular structure and function19.  Between April 
2010 and December 2012, 150 CKF patients were screened and 136 individuals were 
included in the study (three unable to exercise due to physical limitations, eleven did 
not provide consent). Among the essential hypertension subjects, 80 individuals were 
recruited following the exclusion of 5 who had physical co-morbidities precluding 
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exercise testing. All blood samplings and clinical assessments (including office 
brachial blood pressure, echocardiography and vascular tonometry) were performed 
prior to exercise testing. The study was approved by the Black Country Research 
Ethics Committee (REC:09/H1202/113) and adhered to the Declaration of Helsinki. 
Written informed consent was obtained from all eligible participants. 
Cardiopulmonary Exercise Testing 
The CPET was conducted using an electronically braked, upright cycle 
ergometer to maximal tolerance incorporating an individualized work rate. An 
experienced blinded investigator carried out all exercise testing. Before each test, the 
equipment was calibrated using standard reference gases and a 3-litre syringe. Care 
was taken to ensure each study patient understood the maximal exercise test protocol. 
This included explanation of the anticipated early symptoms of lactic acid associated 
leg fatigue or discomfort that must not lead to premature cessation of pedaling or 
incremental loading. Each patient rested for 3 minutes followed by 3 minutes of 
unloaded pedaling prior to workload increments and continuous 12-lead ECG was 
recorded. Continuous breath-by-breath gas exchange analysis (VIASYS, 
MasterScreen CPX®, Hoechberg, Germany) was performed. All patients were 
repeatedly encouraged to continue until symptom limited volitional fatigue. 
The VO2 at the point of anaerobic threshold  (VO2AT) was determined by the V-
slope method in conjunction with analyses of the ventilatory equivalents and end-tidal 
gas tension plots20. VO2peak was measured as the highest VO2 achieved during the 
final 20-second averaging of peak exercise. The predicted VO2peak was determined 
by the Wasserman and Hansen equation20.  
Echocardiographic Study 
2-dimensional, Doppler and tissue Doppler transthoracic echocardiography was 
  7 
performed using Vivid 7, GE Healthcare, Horten, Norway ultrasound system according 
to a standardized study protocol. Calculations included LV ejection fraction according 
to quantitative biplane Simpson’s method, LV end-diastolic volume, LV mass and left 
atrial (LA) volume. Mass and volume measures were indexed to body surface area. 
Tissue Doppler imaging of the mitral annulus, sequentially at the lateral and septal 
annular sites were obtained from the apical 4-chamber view. The ratio of early 
transmitral flow velocity to averaged annular (septal and lateral) mitral velocity 
(E/mean e') was taken as an estimate of LV filling pressure. All measurements were 
undertaken according to the American Society of Echocardiography21 and analyzed 
offline (EchoPac, GE Healthcare) by a blinded investigator. 
Evaluation of Vascular Compliance 
Pulse wave analysis was performed on the radial artery and aortic (carotid-
femoral) pulse wave velocity (PWV) was determined by sequential recording of ECG-
gated carotid and femoral waveforms using the high fidelity micromanometer (SPC-
301, Miller Instrument, Houston, Texas). As augmentation index is influenced by heart 
rate (HR), an index adjusted to a HR of 75 beats/minute (AIx75) was recorded
22. All 
measurements were derived using a validated radial-to-aortic transfer function 
(SphygmoCor, AtCor Medical Pty Ltd, Australia). An experienced operator, masked to 
the echocardiographic and CPET data, made all measurements in triplicate. Mean 
values of all tonometric measurements were used for analysis.  
Statistical Methods 
CKF patients were initially matched to the essential hypertension without CVD 
subjects in age, sex and body mass index (BMI) in a 1:1 ratio using a propensity score 
matching algorithm 23,24. The dataset of a study population consisting of 80 patients in 
each group was subsequently analyzed. Data were presented as mean, median or 
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frequencies depending on the distribution and type of the variable. VO2peak corrected 
for body weight (ml VO2, min
-1 kg-1) was the outcome variable of primary interest in 
this study and was therefore used as the dependent variable for regression modeling 
analyses.  
To identify important predictors of VO2peak a sequence of regression modeling 
analyses were conducted. First CKF and essential hypertension participant data was 
analyzed separately to determine the variables that were predictive of VO2peak within 
each group. Variables that were statistically significant (p<0.05) in the univariate 
analysis were included in the initial multiple linear regression modeling. Stepwise 
elimination, repeated with forward and backward variable selection techniques were 
performed to determine the most important predictors in a multiple regression model 
for each of the groups. Additional to the demographics (age, sex, and BMI), 
adjustments were also made for hemoglobin and duration of hypertension. Logarithmic 
transformation of non-normal distributed data was performed prior to regression 
analysis. Parameter estimate, standard error and 95% confidence interval (CI) were 
calculated for each variable.  
To evaluate the potential adaptive functional cardiovascular changes that 
account for the difference in VO2peak between the two patient groups, variables that 
were statistically significant predictors of VO2peak in multiple regression models were 
additionally assessed by fitting models comprising the interaction term of patient group 
(binary variable) with the predictor variable of interest. The estimate of the interaction 
effect is denoted ∆B and may be interpreted as the difference of the slopes of the 
predictor between the groups. These models were adjusted for age, sex, BMI, 
hemoglobin, duration of hypertension and β-blocker usage. All hypothesis tests were 
two sided and a p–value <0.05 was considered to indicate statistical significance. SAS 
software, version 9.3 (SAS Institute Inc.) was used. (See Supplementary extended 
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methods). 
 
RESULTS 
Clinical characteristics 
 Descriptive characteristics of all the study participants are presented in Table 1. 
CKF patients and subjects with essential hypertension without CVD were adequately 
matched in age (53.3 vs. 53.4 years, p=0.8), sex (male: 56.3 vs. 51.2%, p=0.2) and 
BMI (27.2 vs. 27.6 kg/m2, p=0.6). The use of β-blockers was higher in the CKF 
patients (32.5 vs. 13.8%, p<0.01). Hemoglobin (11.8 vs. 14.2 g/dl, p<0.001), albumin 
(4.4 vs. 4.7 g/dl, p<0.001), LDL-cholesterol (92.8 vs. 112.1 mg/dl, p<0.001) and 
glycated hemoglobin (HbA1c, 5.4 vs. 5.6%, p=0.02) were lower in the CKF patients 
compared to the essential hypertension group.   
 Echocardiographic and applanation tonometric findings of the two groups are 
summarized in Table 2. LV mass index was significantly higher in the CKF than the 
essential hypertension group (109.1 vs. 87.5 g/m2, p<0.001). LV end-diastolic volume 
index (LVEDVI, 48.3 vs. 44.8 ml/m2, p=0.1) was not significantly different between the 
groups. Criteria for LV hypertrophy were present more frequently in CKF patients than 
the hypertensive subjects (45.0 vs. 18.7%, p<0.001). The latter group had a higher LV 
ejection fraction (66.2 vs. 62.6%, p<0.01) than the CKF patients. The measures of 
vascular compliance were not significantly different in both groups.  
Functional cardiovascular reserve in CKF versus essential hypertension 
The metabolic measures of CPET for the two groups are shown in Table 3. All 
patients performed exercise to a level accompanied by a respiratory exchange ratio 
(RER, ratio of CO2 production to O2 consumption) of >1.15. The mean of RER at the 
point of VO2AT for the study populations was 0.9±0.1. Relative to the essential 
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hypertension subjects, the CKF patients had a significantly lower VO2peak (18.8 vs. 
24.5 ml min-1 kg-1, p<0.001; 73.4 vs. 92.9 % predicted, p<0.001) and VO2AT (11.2 vs. 
13.8 ml min-1 kg-1, p<0.001; 43.9 vs. 52.9 % predicted, p<0.001). Essential 
hypertension subjects achieved a longer endurance time (11.9 vs. 10.8 minute, 
p=0.001), tolerated a greater workload (159.9 vs. 106.3 Watt, p<0.001) and more 
reached their predicted peak HR (92.2 vs. 79.7%, p<0.001) compared to CKF 
individuals. 
Independent predictors of VO2peak  
Univariate linear regression analyses for the two groups are presented in Table 
4. Differences between the CKF and essential hypertension populations in the 
unstandardized regression coefficients (b) and estimated regression lines for 
regressing VO2peak onto individual cardiovascular measures are highlighted by 
Figure 1. Increasing LV mass index was positively associated with higher VO2peak in 
the essential hypertension subjects (b=0.21, p<0.001) but not in the CKF population 
(b=-0.01, p=0.9). Higher LVEDVI was associated with a significantly higher VO2peak 
in the hypertensives (b=0.41, p<0.001) but not in the CKF cohort (b=0.01, p=0.7). 
Higher LV filling pressure (E/mean e') was significantly negatively associated with 
VO2peak in the CKF (b=-5.10, p<0.001) but not in the essential hypertension cohort 
(b=-1.37, p=0.7). LV ejection fraction had no association with VO2peak in either group. 
Both AIx75 and PWV had an inverse relationship with VO2peak in the CKF as well as 
the essential hypertension cohorts. 
Cardiac structural variables and VO2peak in the multiple regression models 
 Results of multiple linear regression models for the CKF and essential 
hypertension without CVD populations are presented in Table 5. In the CKF 
population (adjusted R2=0.45), higher E/mean e' was significantly associated with a 
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lower VO2peak (b=-3.55, p=0.001) after adjusting for demographics, hemoglobin and 
duration of hypertension. In the essential hypertension cohort (adjusted R2=0.66), 
larger LVEDVI (b=0.21, p=0.002), LV mass index (b=0.10, p=0.01) and higher peak 
HR were significant predictors of higher VO2peak (b=0.12, p<0.001).  
Associations between cardiac structural variables and VO2peak 
 The effects of the cardiac structural variables on VO2peak in the two groups 
were compared in a model that included the group x predictor interaction terms, 
adjusting for demographics, hemoglobin and duration of hypertension. The regression 
slope for LV mass index predicting VO2peak was steeply more positive in the essential 
hypertension population compared to that of the CKF cohort (∆B=-0.17, 95% CI -0.24 
– -0.10, p<0.001) (Figure 2A). The regression slope for LVEDVI and VO2peak in the 
essential hypertension subjects was also significantly more positive than the CKF 
population (∆B=-0.36, 95% CI -0.47 – -0.24, p<0.001) (Figure 2B).  
Association of arterial stiffness and VO2peak 
 PWV and AIx75 were significant independent predictors of VO2peak in the CKF 
and the essential hypertension subjects (Figure 1E-F; Table 4). Importantly, the 
interaction effect between patient group and both measures of arterial stiffness was 
not significantly different adjusting for demographics, hemoglobin and duration of 
hypertension (Figure 2C-D). Therefore, there is no evidence to suggest that the 
association of arterial stiffness with VO2peak differs between the groups. 
Peak heart rate predicts VO2peak but this relationship is blunted in CKF 
 HR at peak exercise and oxygen pulse were higher among the essential 
hypertension subjects than the CKF cohort (Table 3). HR at peak exercise was also a 
significant independent and adjusted predictor of VO2peak in the essential 
hypertension but not among the CKF patients. The lower peak HR observed in the 
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CKF subjects could be related to a greater use of β-blocker (Table 1). Therefore, the 
effect of peak HR and oxygen pulse on VO2peak were each directly compared 
between the groups in a model that included the group x peak HR or group x oxygen 
pulse interaction terms, adjusting for β-blocker, demographics, hemoglobin and 
duration of hypertension. The regression slope of peak HR was steeper in the 
essential hypertension cohort compared to that of the CKF group (∆B=-0.11, 95% CI -
0.18 – -0.03, p<0.01) (Figure 3A). A similar relationship of oxygen pulse with VO2peak 
was also demonstrated by a steeper regression slope in the essential hypertension 
cohort than the CKF group (∆B=-0.37, 95% CI -0.68 – -0.06, p=0.02) (Figure 3B). 
 
DISCUSSION 
 To our knowledge, this is the first prospective study to evaluate measures of 
arterial-ventricular structure and function and their association with functional 
cardiovascular reserve in subjects with CKF.  While CPET has been used extensively 
in patients with HF, data on objective indices of cardiovascular reserve in patients with 
CKF are scarce. In this study, we have established that VO2peak in ambulant patients 
with CKF was reduced to under 75% of the predicted value.  We have previously 
demonstrated that reduced values of VO2peak, VO2AT and endurance time are 
associated with an increased risk of premature death among CKF patients17. The 
current study demonstrated that each of these parameters was significantly reduced in 
the CKF group compared to the cohort of essential hypertension without CVD. A 
comparable reduced value of VO2peak at 18.6 ml min
-1 kg-1 was documented in two 
prior cycle ergometric studies of patients with CKD by Sietsema et al.14,25 but data on 
the percent-predicted VO2peak, VO2AT and other measures of cardiovascular reserve 
were not available for comparison. In comparison to the patients of Sietsma et al., the 
hemoglobin concentration of our patients was similar (11.8 vs. 11.2 g/dl), but our 
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patients were older (53.3 vs. 46.0 years), had a higher BMI (27.2 vs. 24.5 kg/m2) and a 
lower number of male patients (56.3 vs. 65.0 %); each of these factors might result in 
a lower VO2peak. However, lower prevalence of diabetes (15.0 vs. 18.5 %) and the 
shorter dialysis vintage in our CKF cohort (32.0 vs. 41.5 months) could positively 
impact upon effort tolerance14,25.  
Because the prevalence of hypertension in patients with CKF is near universal, 
we compared the results on our patients with CKF with those of a similar group of 
essential hypertension but without CVD in an effort to differentiate the cardiovascular 
effects of CKF from those of hypertension alone. LV mass was significantly greater in 
the CKF population than the hypertensive controls confirming previous reports that 
hypertension alone does not lead to the myocardial disease known as ‘uremic 
cardiomyopathy’8. The increase in LV mass although paralleled with the high 
prevalence of hypertension in CKF patients26 is thought to be a compensatory 
response to both sustained pressure and volume overload. According to the paradigm 
of adaptive ventricular response to chronic pressure overload in essential 
hypertension, progressive increase in LV mass with thickening of the ventricular wall 
that serves to stabilize and maintain normal wall stress is associated with an increased 
cardiac output and preload27,28. In this study, we demonstrated that incremental LV 
mass changes and end-diastolic volumes in the CKF subjects were not positively 
associated with increments in the VO2peak which contrasted significantly with the 
essential hypertension controls. Even though myocardial growth and remodeling may 
be dynamic adaptive processes that occur early in the course of kidney failure, 
sustained cardiac afterloads exacerbated by uremia in CKF patients could therefore 
lead progressively to maladaptive hypertrophy. A plausible mechanism for this finding 
is that ultra-structural changes within the myocardium such as capillary deficit, fibrillar 
collagen accumulation, fibrosis and calcification alter the compliance and contractility 
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of the LV in patients with CKF to a greater extent than occurs in hypertension resulting 
in a reduced functional cardiovascular reserve5,29   
While the LV ejection fraction in the CKF patients was significantly lower than 
that of hypertensive subjects, this was not predictive of VO2peak.  This finding is 
unsurprising as epidemiological data have shown that up to 50% of patients with HF in 
the absence of significant coronary artery disease have preserved LV ejection 
fraction30. The underlying hemodynamic mechanism leading to exercise intolerance, 
dyspnea and thereby reduced VO2peak
31 in these patients is probably mediated at 
least in part by the increased diastolic LV stiffness32,33. A recent experimental study 
has also indicated that in uremia, the Na+/Ca2+ exchanger mediated calcium extrusion 
from the cytosol of cardiac myocytes is abnormally reduced resulting in impaired 
myocyte relaxation34. The uremic milieu itself may impact adversely on the functional 
cardiovascular reserve as the serum and ultrafiltrate of end-stage kidney disease 
patients have previously been shown to possess negative inotropic and chronotropic 
properties10,35. The latter could explain the blunted HR response to maximal exercise 
in CKF (Figure 3). The suggestion that uremic-related factors may cause blunting of 
the cardiovascular reserve is also supported by published data, albeit from small 
studies which documented improvement in VO2peak following kidney 
transplantation36,37 or augmentation of uremic clearance by intensive nocturnal 
hemodialysis38.  
Higher LV filling pressure was a powerful independent determinant of a reduced 
VO2peak in subjects with CKF.  The elevated LV filling pressure estimate provided by 
E/mean e' reflects the state of impaired cardiomyocyte relaxation39. In CKF, the 
cumulative burden of myocardial fibrosis and LV hypertrophy could cause a reduction 
in the mean e' velocity which further decreases with age40. The resulting impaired LV 
relaxation is a hallmark of diastolic dysfunction33 which has been shown to cause a 
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similar reduction in VO2peak as with systolic dysfunction according to HF studies
31. 
We observed an inverse relationship between LV filling pressure and VO2peak in the 
CKF group which differed markedly from the essential hypertension controls.  
However, the similar measure of LV filling pressure in the two cohorts (Table 2) and 
the lack of association between LV filling pressure and VO2peak in the hypertensives 
suggest that additional mechanistic factors are responsible for the reduced functional 
cardiovascular reserve in CKF.  
 Indices of arterial stiffness were similar between the CKF and hypertensive 
cohorts (Table 2). PWV and AIx75 were significant independent predictors of VO2peak 
(Table 4) in both cohorts. Analysis of individual group interaction with each of the 
arterial measures demonstrated an inverse relationship with VO2peak in both cohorts 
that were not significantly different (Figure 2). Besides being an indirect index of 
arterial stiffness, AIx75 is a measure of pulse wave reflection that calculates how much 
of the central pulse pressure is attributable to accelerated pressure wave reflection41. 
This pathological wave reflection increases cardiac loading and prejudices the 
diastolic coronary perfusion41-43 which could aggravate the cardiovascular reserve. We 
postulate that the potential contribution of large artery compliance to functional 
cardiovascular reserve may, in part, be mediated by LV compliance44,45 and the loss of 
adaptive functional LV changes in the CKF.  
Limitations  
 Exercise training has been shown to improve VO2peak
46 but data on muscle 
mass or strength were not collected in this study. Despite these, extensive evaluation 
of the ventricular-vascular function and dynamics were carried out resulting in novel 
and important information on how these cardiovascular alterations could adversely 
impact the VO2peak in CKF. Also, Painter et al.
47 had previously shown that muscle 
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conditioning through supervised five-month exercise training and normalization of 
hematocrit improved but failed to normalize VO2peak in hemodialysis-dependent 
patients, indicating other physiological contributors to the reduced cardiovascular 
reserve in these patients. 
In conclusion, our study shows that there are complex cardiovascular 
alterations in CKF that are associated with reduced functional cardiovascular reserve. 
Our findings provide a pathophysiological background for appreciating the association 
between the maladaptive ventricular-vascular dynamics and reduced VO2peak in CKF.  
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Figure Legends 
 
Figure 1: Scatterplots of cardiovascular measures with VO2peak among the  
CKF and essential hypertension (HTN) cohorts 
Grey circles represent the HTN cohort and the black circles represent the CKF cohort. 
The dashed and straight lines are unadjusted regression lines for the CKF and the 
HTN cohorts respectively. b, unstandardized regression coefficient: change in ml 
VO2peak, min
-1 kg-1 per one unit change of variable. aLog-transformed. *p–value<0.05. 
 
Figure 2: Difference of changes in VO2peak with LV mass index (A), LVEDVI (B) and  
arterial stiffness (C, D) between the CKF and essential hypertension (HTN) 
cohorts 
∆B is the difference in the parameter estimates between the regression lines for the 
HTN and CKF groups. Group interaction with LV mass index (A), LVEDVI (B), PWV 
(C) and AIx75 (D) were adjusted for demographics, hemoglobin and duration of 
hypertension. Dash line=HTN, straight line=CKF. aLog-transformed. *p–value<0.05. 
 
Figure 3: Changes in VO2peak with peak HR (A) and oxygen pulse (B) differ between  
      the CKF and essential hypertension (HTN) cohorts 
∆B is the difference in the parameter estimates between the regression lines for HTN 
and CKF groups. Group interaction with peak HR (A) and oxygen pulse (B) were 
adjusted for β-blocker usage, demographics, hemoglobin and duration of 
hypertension. Dash line=HTN, straight line=CKF. *p–value<0.05.  
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Supplementary Materials 
 
 
Supplementary extended methods 
- Clinical Data 
- Evaluation of Vascular Compliance 
- Statistical Methods 
 
Table S1: Characteristics of the CKF cohort 
Data are mean ± SD, median (IQR) or frequencies (%). P–value by independent-samples 
t-test or Mann-Whitney U (continuous variables) and χ2 (categorical variables). BMI, body 
mass index; BP, blood pressure; ACEi, angiotensin-converting-enzyme inhibitor; ARB, 
angiotensin-receptor blocker; eGFR, estimated glomerular filtration rate; HbA1c, glycated 
hemoglobin; LDL, low density lipoprotein (in mg/dl to mmol/l, x0.02586). Phosphate in 
mg/dl to mmol/l, x0.3229; creatinine in mg/dl to μmol/l, x88.4. *p–value<0.05. 
 
Table S2: Multiple regression analysis of VO2peak in the CKF and the essential  
hypertension populations 
aAll models adjusted for demographic variables age, sex, BMI, hemoglobin and 
duration of hypertension. bLog-transformed prior to analysis. b, unstandardized 
regression coefficient: change in ml VO2peak, min
-1 kg-1 per one unit change of 
variable. †Final model derived through variable selection process from variables in 
models. *p–value<0.05. 
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Table 1: Characteristics of the study population 
Variables †CKF (n=80) HTN (n=80) p–value 
Age, years 53.3 ± 9.1 53.4 ± 8.2 0.8 
Male, n (%) 45 (56.3) 41 (51.2) 0.2 
BMI, kg/m2 27.2 ± 4.7 27.6 ± 3.6 0.6 
Smoking, n (%) 41 (51.3) 43 (53.7) 0.8 
Hypertension, n (%) 71 (88.8) 80 (100.0) <0.01* 
Duration of hypertension, months 120 (48 – 228) 60 (36 -120) 0.02* 
Systolic BP, mm Hg 135.8 ± 23.9 140.9 ± 12.8 0.1 
Diastolic BP, mm Hg 79.1 ± 11.6 85.4 ± 9.8 0.001* 
Pulse pressure, mm Hg 57.0 ± 18.3 55.5 ± 12.1 0.5 
Antihypertensives    
  ACEi/ARB, n (%) 25 (31.3) 47 (58.8) <0.001* 
  Calcium antagonist, n (%) 42 (52.5) 34 (42.5) 0.2 
  β-blocker, n (%) 26 (32.5) 11 (13.8) <0.01* 
  Diuretics, n (%) 12 (15.0) 35 (43.8) <0.001* 
Co-morbidities    
  Diabetes mellitus, n (%) 12 (15.0) 0  
  Prior cardiovascular disease, n (%) 10 (12.5) 0  
  Dialysis, n (%) 61 (76.3) 0  
       Dialysis vintage, months 32 (15 – 60) -  
       Urea reduction ratio, % 69.8 ± 8.6 -  
Biochemical    
  Creatinine, mg/dl - 0.8 ± 0.2  
  eGFR, ml/min/1.73m2 - 92.6 ± 15.2  
  Hemoglobin, g/dl 11.8 ± 1.3 14.2 ± 1.2 <0.001* 
  C-reactive protein, mg/dl 0.3 (0.0 – 0.7) 0.3 (0.3 – 0.4) 0.8 
  Albumin, g/dl 4.4 (4.2 – 4.5) 4.7 (4.6 – 4.8) <0.001* 
  Phosphate, mg/dl 4.6 (3.7 – 5.3) 3.4 (3.1 – 3.7) <0.001* 
  HbA1c, % 5.4 (5.2 – 5.9) 5.6 (5.4 – 5.9) 0.02* 
  LDL cholesterol, mg/dl 92.8 ± 38.7 112.1 ± 34.8 <0.001* 
Data are mean ± SD, median (IQR) or frequencies (%). P–value by paired-samples t-test or 
Wilcoxon (continuous variables) and χ2 (categorical variables). BMI, body mass index; BP, 
blood pressure; ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin-receptor 
blocker; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; LDL, low 
density lipoprotein (in mg/dl to mmol/l, x0.02586). Phosphate in mg/dl to mmol/l, x0.3229; 
creatinine in mg/dl to μmol/l, x88.4.  †For clinical characteristics of dialysis-dependent and 
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non-dialysis CKF cohort, please refer to Table S1 (supplementary). *p–value<0.05. 
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Table 2: Measures of cardiac function and vascular compliance 
Variables CKF (n=80) HTN (n=80) p–value 
Cardiac     
  LV mass index, g/m2 109.1 ± 33.4 87.5 ± 17.1 <0.001* 
  LV geometry, n (%)   <0.001* 
    Normal geometry 12 (15.0) 27 (33.7)  
    Concentric remodeling 32 (40.0) 38 (47.6)  
    Concentric hypertrophy 24 (30.0) 6 (7.5)  
    Eccentric hypertrophy 12 (15.0) 9 (11.2)  
  LVEDVI, ml/m2 48.3 ± 18.1 44.8 ± 10.1 0.1 
  LA volume index, ml/m2 25.4 (18.6 – 31.6) 25.7 (19.8 – 30.5) 0.7 
  LV ejection fraction, % 62.6 ± 7.9 66.2 ± 5.7 <0.01* 
  Transmitral E/A 0.8 (0.7 – 1.0) 1.0 (0.8 – 1.2) <0.001* 
  Deceleration time, ms 222.4 ± 64.6 202.0 ± 50.4 0.03* 
  Mean e', m/s 8.6 ± 2.2 8.9 ± 2.2 0.4 
  E/mean e' 8.3 (6.6 – 10.5) 8.3 (7.0 – 9.1) 0.2 
Vascular    
  Tr, ms 135.7 ± 11.8 137.4 ± 12.2 0.4 
  AIx75, % 26.9 ± 11.8 25.4 ± 11.9 0.5 
  PWV (m/s) 8.4 (7.3 – 9.7) 8.5 (7.9 – 9.6) 0.4 
  Ea, mmHg/ml 2.6 ± 1.2 2.4 ± 0.7 0.09 
Data are mean ± SD, median (IQR) or frequencies (%). P–value by paired-samples t-test or 
Wilcoxon (continuous variables) and χ2 (categorical variables). LV, left ventricular; LVEDVI, LV 
end-diastolic volume index; LA, left atrium; E/A, the ratio of peak early to late transmitral 
ventricular filling velocities; mean e', averaged septal and lateral annular mitral velocity; Tr, 
time to reflection; AIx75, augmentation index adjusted to heart rate of 75 beats/min; PWV, 
pulse wave velocity; Ea, arterial elastance. *p–value<0.05. 
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Table 3: Measures of functional cardiovascular reserve 
Data are mean ± SD and median (IQR). P–value by paired-samples t-test or Wilcoxon test. 
VO2peak, oxygen consumption at peak exercise; VO2AT, oxygen consumption at the point of 
anerobic threshold; VE-VCO2, ventilatory equivalent for carbon dioxide; RER, respiratory 
exchange ratio of CO2 production to O2 consumption; HR, heart rate. *p–value<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables CKF (n=80) HTN (n=80) p–value 
VO2peak, ml min
-1 kg-1 18.8 ± 4.1 24.5 ± 7.1 <0.001* 
VO2peak, % predicted
 73.4 ± 15.0 92.9 ± 20.4 <0.001* 
VO2AT, ml min
-1 kg-1 11.2 ± 2.1 13.8 ± 3.6 <0.001* 
VO2AT, % predicted VO2peak 43.9 ± 8.7 52.9 ± 11.4 <0.001* 
VE-VCO2 slope 29.3 (27.4 – 33.9) 28.5 (26.7 – 30.9) 0.06 
Maximal work load, Watt 106.4 ± 38.8 159.3 ± 59.9 <0.001* 
Endurance time, min 10.8 (9.2 – 12.1) 11.9 (10.5 – 12.8) 0.003* 
RER at VO2AT 0.9 ± 0.1 0.9 ± 0.1 0.7 
RER at peak exercise  1.3 ± 0.1 1.2 ± 0.1 <0.001* 
HR at peak exercise, beat min-1 132.8 ± 22.5 155.4 ± 19.4 <0.001* 
HR at peak exercise,% predicted 79.7 ± 12.9 92.2 ± 14.1 <0.001* 
Oxygen pulse, ml O2 min
-1 10.4 (9.0 – 14.0) 11.7 (9.1 – 14.8) 0.04* 
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Table 4: Univariate regression analysis of VO2peak in the study population   
Variables 
CKF HTN 
b 95% CI b 95% CI 
Age -0.08 -0.18 – 0.02 -0.34 -0.53 – -0.16† 
Sex (Female) -2.89 -4.61 – -1.17† -6.48 -9.35 – -3.61† 
BMI -0.16 -0.35 – 0.03 -0.11 -0.56 – 0.34 
Smoking (Ever) -0.73 -2.54 – 1.09 -1.40 -4.62 – 1.81 
Duration of hypertension -0.01 -0.02 - -0.01¥ -0.01 -0.02 – 0.02 
Diabetes (Present) -1.64 -4.16 – 0.89 - - 
Dialysis vintage -0.01 -0.04 – 0.01 - - 
HR at peak exercise 0.02 -0.02 – 0.07 0.17 0.10 – 0.25† 
AIx75 -0.10 -0.17 – -0.02
‡ -0.23 -0.35 – -0.10† 
aPWV -3.96 -7.53 – -0.40¥ -8.77 -16.77 – -0.78¥ 
LV mass index -0.01 -0.03 – 0.03 0.21 0.13 – 0.30† 
LA volume index -0.05 -0.13 – 0.03 0.07 -0.15 – 0.28 
LV ejection fraction 0.05 -0.07 – 0.16 -0.22  -0.50 – 0.06 
LVEDVI 0.01 -0.04 – 0.06 0.41 0.28 – 0.54† 
Transmitral E/A -2.90 -5.76 – 0.04 6.45 0.95 – 11.94¥ 
aE/mean e' -5.10 -7.40 – -2.81† -1.37 -8.97 – 6.22 
Hemoglobin 0.72 0.05 – 1.39¥ 1.45 0.14 – 2.76¥ 
C-reactive protein -0.05 -0.13 – 0.03 -0.55 -1.55 – 0.46 
Albumin 0.26 -0.03 – 0.56 0.91 0.18 – 1.64¥ 
Phosphate -1.49 -3.68 – 0.69 -4.25 -10.10 – 1.61 
HbA1c -0.56 -1.55 – 0.43 -4.00 -8.32 – 0.32 
LDL cholesterol -0.27 -1.21 – 0.66 -0.47 -2.35 – 1.41 
Urine PCR 0.00 -0.01 – 0.01 -0.06 -0.15 – 0.04 
a
Log-transformed prior to analysis. b, unstandardized regression coefficient: change in ml 
VO2peak, min
-1 kg-1 per one unit change of variable. Statistical significance of the 
regression coefficient as determined by p–value: ≤0.001†, ≤0.01‡, <0.05¥.   
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Table 5: Multiple regression analysis of VO2peak in the CKF and the essential   
    hypertension populations 
aModels b 
Standard 
Error 
95% CI p–value 
CKF (n = 80); (unadjusted R2 = 0.51, adjusted R2 = 0.45) 
    Intercept 33.18 5.64 21.90 – 44.46 <0.001* 
    bE/mean e' -3.55 1.05 -5.66 – -1.45 0.001* 
    AIx75 -0.07 0.04 -0.15 – 0.02 0.1 
    bPWV -1.31 1.67 -4.66 – 2.03 0.4 
Essential hypertension (n = 80); (unadjusted R2 = 0.71, adjusted R2 = 0.66) 
    Intercept -12.02 18.26 -48.52 – 24.47 0.5 
    Transmitral E/A 1.76 2.12 -2.47 – 5.99 0.4 
    LVEDVI 0.21 0.07 0.09 – 0.34 0.002* 
    LV mass index 0.10 0.04 0.02 – 0.17 0.01* 
    AIx75 -0.06 0.06 -0.17 – 0.05 0.3 
      bPWV -1.97 3.03 -8.02 – 4.09 0.5 
    HR at peak exercise 0.12 0.03 0.07 – 0.18 <0.001* 
    Albumin 0.24 0.27 -0.30 – 0.79 0.4 
 a
All models including final models (see Table S2 - supplementary) adjusted for 
demographic variables age, sex, BMI, hemoglobin and duration of hypertension. 
b
Log-
transformed prior to analysis. b, unstandardized regression coefficient: change in ml 
VO2peak, min
-1 kg-1 per one unit change of variable.  *p–value<0.05. 
 
 
 
 
 
 
 
 
